Physician profile
Katlyn S Hansen
NPI 1649693326
$8,456.07
in general payments reported to CMS, 2019-2025
25 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,501 · 2022: $1,680 · 2023: $1,323 · 2024: $1,600 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,930 · Education: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,929.79 |
| Education | $344.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,974.95 | 2021-2025 | |
| Janssen Biotech, INC. | $2,042.54 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $903.83 | 2021-2025 | Livdelzi, Epclusa |
| Madrigal Pharmaceuticals | $501.01 | 2024-2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $467.49 | 2021-2025 | Entyvio |
| Genzyme Corporation | $360.55 | 2022-2025 | |
| Ardelyx, INC. | $287.46 | 2022-2023 | Ibsrela |
| Janssen Scientific Affairs, LLC | $227.21 | 2021-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $147.81 | 2021 | |
| Ferring Pharmaceuticals INC. | $83.22 | 2021-2023 | Clenpiq |
| Regeneron Healthcare Solutions, INC. | $73.37 | 2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.32 | 2021-2022 | |
| Celgene Corporation | $54.11 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.01 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $32.96 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $32.22 | 2023 | |
| Celltrion USA INC. | $25.65 | 2024 | Zymfentra |
| Vivus LLC | $25.60 | 2021 | |
| Phathom Pharmaceuticals, INC. | $24.05 | 2024 | Voquezna |
| Amgen INC. | $20.48 | 2023 | Amjevita, Avsola |
| Redhill Biopharma INC. | $19.54 | 2021 | |
| Pfizer INC. | $18.53 | 2025 | |
| Qol Medical, LLC | $17.96 | 2024 | Sucraid |
| Pacira Pharmaceuticals Incorporated | $15.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katlyn Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.